Why Is KODIAK SCIENCES INC (KOD) Stock Up Today?

KOD stock surged 177.96% to $89.92 in a single session driven by positive Phase 3 trial results for its wet AMD therapies. The DAYBREAK trial showed that Zenkuda and tabirafusp-ted met primary endpoints and matched Regeneron’s Eylea in efficacy. The results have triggered renewed investor interest and multiple price target upgrades.

What Happened

Kodiak Sciences Inc. announced top-line data from its Phase 3 DAYBREAK trial, demonstrating that its long-acting eye treatments are effective and durable. The therapies matched a leading competitor’s drug in key metrics, which has led to a sharp rise in the stock. The company also released a slide deck detailing the results on September 28. This development has been widely covered in the financial media, with several analysts revising their price targets upward. Jefferies raised its target to $112 from $56, while LifeSci Capital increased its target to $145 from $85. UBS also raised its target to $120 and maintained a Buy rating.

Retail traders on social platforms noted the stock’s dramatic rise, with some calling it a “real deal” and citing the long-lasting nature of the therapies. Competitor OCUL experienced a sharp selloff on the same day, as investors shifted money to Kodiak and other firms with recent clinical updates.

What The Data Shows

The stock has gained 140.1% over the last eight sessions, climbing from $32.85 to $78.87. Intraday unusual options activity included three notable prints, with put premiums totaling $2.5 million and the largest single print at $1.9 million. The stock closed at a new 52-week high on September 28, marking 26 fresh highs that day. Despite the rally, the stock remains unprofitable with an EPS TTM of -4.18 and a high beta of 2.18. The 52-week range is $10.94 to $47.84, indicating the move is well beyond prior levels.

What To Watch

Kodiak Sciences has not scheduled an earnings report, but coverage breadth is expanding rapidly. Investors should monitor further analyst reactions and potential follow-up data releases from the company.